THE SYMBOL [***] DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH COMPANY IF PUBLICLY DISCLOSED. SHARE SALE AND PURCHASE AGREEMENT among SAGA INVESTMENTS COÖPERATIEF U.A. as the Seller and...Sale and Purchase Agreement • September 13th, 2022 • NewAmsterdam Pharma Co B.V. • Pharmaceutical preparations
Contract Type FiledSeptember 13th, 2022 Company Industry
THE SYMBOL [***] DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH COMPANY IF PUBLICLY DISCLOSED. PROFIT RIGHT AND WAIVER AGREEMENT among NEWAMSTERDAM PHARMA B.V. and DEZIMA PHARMA B.V. and...Profit Right and Waiver Agreement • September 13th, 2022 • NewAmsterdam Pharma Co B.V. • Pharmaceutical preparations • New York
Contract Type FiledSeptember 13th, 2022 Company Industry Jurisdiction
NewAmsterdam Pharma Holding B.V. Gooimeer 2-35 1411 DC Naarden The Netherlands Naarden, 20 July 2022 BY ELECTRONIC TRANSMISSION Saga Investments Coöperatief U.A. Mr. J.A. Bouman WITH COPY TO Andrew Turney Associate General Counsel, AmgenNewAmsterdam Pharma Co B.V. • September 13th, 2022 • Pharmaceutical preparations
Company FiledSeptember 13th, 2022 IndustryReference is made to the share sale and purchase agreement among Saga Investments Coöperatief U.A. (“Amgen” or “you”), NewAmsterdam Pharma Holding B.V. (formerly NewAmsterdam Pharma B.V.) (“NAP” or “us”) and Dezima Pharma B.V. (the “Company”) dated 9 April 2020 regarding the acquisition by NAP of all issued shares in the share capital of the Company (the “SPA”). Unless stated otherwise herein, capitalized terms used in this letter agreement shall have the same meaning as ascribed thereto in the SPA.
NewAmsterdam Pharma Holding B.V. Gooimeer 2-35 1411 DC Naarden The Netherlands Naarden, 20 July 2022 BY ELECTRONIC TRANSMISSION Mitsubishi Tanabe Pharma CorporationNewAmsterdam Pharma Co B.V. • September 13th, 2022 • Pharmaceutical preparations
Company FiledSeptember 13th, 2022 IndustryReference is made to the profit right and waiver agreement among Mitsubishi Tanabe Pharma Corporation (“MTPC” or “you”), NewAmsterdam Pharma Holding B.V. (formerly NewAmsterdam Pharma B.V.) (“NAP” or “us”) and Dezima Pharma B.V. (the “Company”) dated 9 April 2020 regarding the waiver by MTPC of certain then-existing rights in connection with the acquisition of all shares in the share capital of the Company by Saga Investments Coöperatief U.A. (the “Agreement”). Unless stated otherwise herein, capitalized terms used in this letter agreement shall have the same meaning as ascribed thereto in the Agreement.